Results 71 to 80 of about 37,162 (308)

Latent Trajectories of Body Mass Index and Depressive Symptoms in Inpatients With Anorexia Nervosa: Predictors and Outcomes

International Journal of Eating Disorders, EarlyView.
ABSTRACT Objective Inpatient treatment aimed at weight restoration and psychiatric stabilization is often required for individuals with anorexia nervosa (AN). This study aimed to identify distinct trajectories of change in body mass index (BMI) and depressive symptoms during inpatient treatment, examine clinical predictors and outcomes, and test ...
Matteo Martini, Mie Sedoc Jørgensen, Cristiano Dani, Anne Bryde Christensen, Magnus Sjögren, Nadia Micali   +5 more
wiley   +1 more source

Antipsychotic drugs and risks of myocardial infarction: a self-controlled case series study. [PDF]

, 2014
AIM: Antipsychotics increase the risk of stroke. Their effect on myocardial infarction remains uncertain because people prescribed and not prescribed antipsychotic drugs differ in their underlying vascular risk making between-person comparisons difficult
Anaya-Izquierdo, Karim, Brauer, Ruth, Denaxas, Spiros C, Douglas, Ian, Farrington, C Paddy, Hemingway, Harry, Smeeth, Liam, Timmis, Adam, Whitaker, Heather   +8 more
core   +2 more sources

Faecal Microbiota Transplantation in Anorexia Nervosa: A Systematic Review of Methodologies, Outcomes, and Challenges With Recommendations for Future Studies

European Eating Disorders Review, EarlyView.
ABSTRACT Objective Anorexia nervosa (AN) is a severe psychiatric disorder displaying an altered gut microbiome. Faecal microbiome transplantation (FMT) has emerged as a powerful research tool and potential treatment option in AN due to the microbiome‐gut‐brain axis. Current studies are limited and reveal variable FMT protocols.
Anna C. Thelen, Nele M. Korten, Larissa Blischke, Clara Voelz, Cordian Beyer, Jochen Seitz, Stefanie Trinh   +6 more
wiley   +1 more source

Dietary and biomarker‐guided strategies as supportive measures in the fragile X syndrome

Food Biomacromolecules, EarlyView.
Abstract The fragile X syndrome (FXS) is an inherited neurodevelopmental disorder that primarily affects males, often resulting in an IQ below 55, while about two‐thirds of females also experience intellectual disability. Physical features may include an elongated face, prominent ears, finger joint laxity, and enlarged testes in males.
Jailan E. El Halawani, Reem R. AlOlaby
wiley   +1 more source

Atypical antipsychotic therapy in Parkinson's disease psychosis: A retrospective study. [PDF]

, 2017
ObjectiveParkinson's disease psychosis (PDP) is a frequent complication of idiopathic Parkinson's disease (iPD) with significant impact on quality of life and association with poorer outcomes.
Bizzarri, Cummings, Fernandez, Fernandez, Fénelon, Gama, Goldman, Hack, Hubbard, Kiferle, Lertxundi, McFarland, Meltzer, Meral, Mesquita, Mocci, Munhoz, Noel, Pagonabarraga, Prohorov, Rabey, Reichmann, Rolland, Seppi, Shotbolt, Starkstein, Thomas, Vanover, Weintraub, Zhu   +29 more
core   +2 more sources

Antipsychotic prescribing patterns and determinants in first-episode psychosis: a 2019–2024 cross-sectional study from Zambia

BMC Psychiatry
Background First-episode psychosis represents a critical period in psychotic disorders, during which timely, appropriate treatment can greatly influence long-term outcomes.
Lihlizulu Thabo Moyo, Thandiwe Martha Tembo, Brian Maila   +2 more
doaj   +1 more source

Antipsychotics for the treatment of bipolar disorder

Psychiatry and Clinical Psychopharmacology, 2021
Antipsychotics are commonly used in bipolar disorders both for the treatment of acute episodes and of maintenance. However, the use of typical antipsychotics in bipolar episodes is associated with a number of limitations.
Cengiz Tuğlu
doaj  

Is obstructive sleep apnea the missing link between metabolic syndrome and second-generation antipsychotics: Preliminary study

Indian Journal of Psychiatry, 2018
Background: Metabolic syndrome in individuals taking second-generation antipsychotics is thought to be mediated by antipsychotic-induced weight gain. However, recent literature challenges this notion, and theoretically, it may also be mediated through ...
Rupali Rohatgi, Ravi Gupta, Rajat Ray, Vinita Kalra   +3 more
doaj   +1 more source

Antipsychotic dose escalation as a trigger for Neuroleptic Malignant Syndrome (NMS): literature review and case series report [PDF]

, 2012
Background: “Neuroleptic malignant syndrome” (NMS) is a potentially fatal idiosyncratic reaction to any medication which affects the central dopaminergic system. Between 0.5% and 1% of patients exposed to antipsychotics develop the condition.
AL Pelonero, BD Berman, D Berardi, D Bereardi, D Heyland, Daniel J Smith, Daniel Martin, F-GB Pajonk, H Itoh, J Ananth, J Delay, J Gill, JF Patterson, JN Trollor, JR Strawn, Julie Langan, K Otani, KL Hall, LF Viejo, LS Friedman, M Dave, MJ Bhanushali, P Adnet, P Sachdev, P Sachdev, PE Keek, PF Buckley, PI Rosebush, PJ Alexander, Polash Shajahan, RJ Gurrera, RJ Gurrera, RW Baker, S Caroff, S Madakasira   +34 more
core   +3 more sources

Impact of the Unified Protocol on Attenuated Psychotic Symptoms, Cognitive Biases and Cognitive Insight in Patients at Ultra High Risk (UHR) for Psychosis: Secondary Results of a Pilot Randomized Controlled Trial

Journal of Clinical Psychology, EarlyView.
ABSTRACT Background and Hypothesis Ultra high risk (UHR) for psychosis can have different clinical trajectories but the remission rates are only 51.9% after 3 years of follow‐up. Deficits in metacognition are associated with severity of symptoms and poor response to treatment.
Trinidad Peláez, Raquel López‐Carrilero, Victoria Espinosa, Sol Balsells, Paolo Fusar‐Poli, Susana Ochoa, Jorge Osma   +6 more
wiley   +1 more source